CSTLCastle Biosciences, Inc.
$33.72+47% 1Y
$33.72
$18.1552 weeks$43.04
The financials
Castle Biosciences, Inc. by the numbers
Castle Biosciences, Inc. (CSTL) reported revenue of $104M in Q2 2026 (quarter ended Jun 30, 2026), up 20% from the same quarter a year earlier. That came with a gross margin of 77% and net loss of $2.1M. For the full year FY2025, revenue was $344M (+3.7% year on year) and net income −$24M. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $104M | $86M | +20% |
| Gross profit | $80M | $69M | +16% |
| Operating income | −$3.1M | −$4.3M | n/a |
| Net income | −$2.1M | $4.5M | to a loss |
| Diluted EPS | −$0.07 | $0.15 | to a loss |
Diagnostics & Research
Ranks #11 of 21 by RyuScore